Evidence map›Paper›PMID 39474589›Full record

ReviewCureus2024

Induced Native Phage Cocktails for Multi-microbial Activation Syndrome in Treatment-Resistant Illnesses.

David A Jernigan

Abstract readReview
In one paragraph

Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

David A JerniganBioregulatory Medicine, Biologix Center for Optimum Health, Franklin, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The global population is plagued by chronic illnesses of many types due to, in part, the activation of virulence of many latent microbes leading to chronic multi-system illness, stimulating the new term, multi-microbial activation syndrome (MMAS). Treatment-resistant infections across the entire microbial spectrum are now largely untreatable using the previously successful pharmaceutical and natural medicine options. The heavy-handed methods of long-term chemotherapeutic antibiotics, antifungals, and antiviral drugs, whose adverse effects could be worse than the original illness, are presently essentially useless in the long run, as microbes have developed rapid adaptive mutations, becoming drug-resistant. The introduction of induced native phage therapy opened a completely new treatment category that has the potential to complement or replace aggressive drug therapies of many classes. Since its introduction, many advancements have been made to the technology. The most recent development in this new treatment genre is the ability to formulate induced native phage cocktails that use a wide spectrum of induction signatures within the formulation to stimulate various types of beneficial phages already living within the phageome of the body, to target a wide range of pathogenic microbes and associated advantageous physiological targets. The ability to address the MMAS commonly seen in various chronic illnesses simultaneously within the same formulation enables greater clinical outcomes without harm to the microbiome or to the tissues and systems of the body.

Indexed as

biofilmbiospectral emission sequencingendotoxininduced native phage therapyinducen-ld/rfinducen-reslyme diseasemulti-microbial activation syndromerespiratory tract infections

Identifiers

PMID39474589
PMCPMC11518919

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.